Mutations Position Table
PSEN1 M146 Mutations
Mutation | Clinical Phenotype |
Pathogenicity | Neuropathology | Biological Effect | Genomic Position | Genomic Region | Mutation Type Codon Change |
Research Models |
Primary Papers |
---|---|---|---|---|---|---|---|---|---|
M146I (G>A) |
Alzheimer's Disease | Alzheimer's Disease : Pathogenic | Neuropathology consistent with AD. |
Increased Aβ42/Aβ40 and Aβ42/Aβ38; unchanged Aβ38/Aβ40 and Aβ43/Aβ40 in iPSC-derived neurons, suggesting inefficient carboxypeptidase activity.Variable protein levels, consistent with altered protein stability. Also, disrupted lysosome function and autophagy seemingly due to accumulation of β-C-terminal APP fragments. |
rs63750391 |
Coding Exon 5 |
Point, Missense ATG to ATA |
0 | Jørgensen et al., 1996 |
M146I (G>C) |
Alzheimer's Disease | Alzheimer's Disease : Pathogenic | Neuropathology consistent with AD in 3 cases, but more involvement of central grey areas, no vascular lesions, and very mild amyloid angiopathy. |
Increased Aβ42/Aβ40 and Aβ42/Aβ38; unchanged Aβ38/Aβ40 and Aβ43/Aβ40 in iPSC-derived neurons, suggesting inefficient carboxypeptidase activity. Variability in mutant protein levels, consistent with altered protein stability. Also, disrupted lysosome function and autophagy seemingly due to accumulation of β-C-terminal APP fragments. |
rs63750391 |
Coding Exon 5 |
Point, Missense ATG to ATC |
0 | Gustafson et al., 1998 |
M146I (G>T) |
Alzheimer's Disease | Alzheimer's Disease : Not Classified | Unknown, but carriers of a different nucleotide mutation resulting in the same amino acid substitution had neuropathology consistent with AD. |
Increased Aβ42/Aβ40 and Aβ42/Aβ38; unchanged Aβ38/Aβ40 and Aβ43/Aβ40 in iPSC-derived neurons, suggesting inefficient carboxypeptidase activity. High degree of variablilty in mutant protein levels, consistent with altered protein stability. Also, disrupted lysosome function and autophagy seemingly due to accumulation of β-C-terminal APP fragments. |
rs63750391 |
Coding Exon 5 |
Point, Missense ATG to ATT |
0 | Rogaeva et al., 2001 |
M146L (A>C) |
Alzheimer's Disease, Pick's disease | Alzheimer's Disease : Pathogenic | Neuropathology consistent with AD in multiple affected mutation carriers. Pick bodies and Lewy body pathology, as assessed by α-synuclein staining, have been noted in some cases. |
Increased Aβ42/Aβ total ratio, Aβ42/Aβ40 ratio, and Aβ42. Disrupted calcium dynamics and mitochondrial permeability. |
rs63750306 |
Coding Exon 5 |
Point, Missense ATG to CTG |
14 | Sherrington et al., 1995; Sorbi et al., 1995; , 1995 |
M146L (A>T) |
Alzheimer's Disease | Alzheimer's Disease : Pathogenic | Neuropathology consistent with AD. In one case, Lewy body pathology in the amygdala, cingulate gyrus, and substantia nigra. |
Increased Aβ42, Aβ42/Aβ total, Aβ42/Aβ40 in cells and in vitro assays. Impaired calcium dynamics and mitochondrial permeability. |
rs63750306 |
Coding Exon 5 |
Point, Missense ATG to TTG |
0 | Mangone et al., 1995; Morelli et al., 1998 |
M146V |
Alzheimer's Disease, Frontotemporal Dementia | Alzheimer's Disease : Pathogenic, Frontotemporal Dementia : Not Classified | Variable: Neuropathology consistent with AD in some cases, but also, in at least one case, mixed pathology including frequent Aβ deposits, tangles, and Pick bodies. |
Increased Aβ42/Aβ40 ratio; increased Aβ42 and Aβ43; lowered wild-type PSEN1 gene expression. Disrupted endosomes via accumulation of APP β-CTF. Disrupted calcium channels, triggered cascade resulting in altered axonal transport, damage/loss of neurites. Increased calcineurin activity, impaired trafficking of glutamate AMPA receptors. Disrupted mitochondrial function, altered trophic factor function, and cerebral blood flow. |
rs63750306 |
Coding Exon 5 |
Point, Missense ATG to GTG |
6 | , 1995 |
Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.